DK2890711T3 - Process for Preparation of Inter-species, Intra-Target Cross-Reactivity Antibody Molecules - Google Patents
Process for Preparation of Inter-species, Intra-Target Cross-Reactivity Antibody Molecules Download PDFInfo
- Publication number
- DK2890711T3 DK2890711T3 DK13753659.5T DK13753659T DK2890711T3 DK 2890711 T3 DK2890711 T3 DK 2890711T3 DK 13753659 T DK13753659 T DK 13753659T DK 2890711 T3 DK2890711 T3 DK 2890711T3
- Authority
- DK
- Denmark
- Prior art keywords
- species
- human
- antibodies
- antigen
- target
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 42
- 230000009260 cross reactivity Effects 0.000 title claims description 32
- 241000894007 species Species 0.000 claims description 76
- 239000000427 antigen Substances 0.000 claims description 50
- 102000036639 antigens Human genes 0.000 claims description 50
- 108091007433 antigens Proteins 0.000 claims description 50
- 241000282414 Homo sapiens Species 0.000 claims description 42
- 102100022723 Interleukin-22 receptor subunit alpha-1 Human genes 0.000 claims description 32
- 101001044883 Homo sapiens Interleukin-22 receptor subunit alpha-1 Proteins 0.000 claims description 30
- 241001465754 Metazoa Species 0.000 claims description 13
- 235000002198 Annona diversifolia Nutrition 0.000 claims description 9
- 241000283984 Rodentia Species 0.000 claims description 9
- 241000282842 Lama glama Species 0.000 claims description 8
- 241000282832 Camelidae Species 0.000 claims description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 31
- 230000027455 binding Effects 0.000 description 26
- 101000662009 Homo sapiens UDP-N-acetylglucosamine pyrophosphorylase Proteins 0.000 description 6
- 102100037921 UDP-N-acetylglucosamine pyrophosphorylase Human genes 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000036515 potency Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 108010074109 interleukin-22 Proteins 0.000 description 2
- 108010087904 neutravidin Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241001244729 Apalis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101001010626 Homo sapiens Interleukin-22 Proteins 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000282852 Lama guanicoe Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261695664P | 2012-08-31 | 2012-08-31 | |
| PCT/EP2013/067979 WO2014033252A1 (en) | 2012-08-31 | 2013-08-30 | Method for producing antibody molecules having inter-species, intra-target cross-reactivity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2890711T3 true DK2890711T3 (en) | 2017-02-27 |
Family
ID=49080903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13753659.5T DK2890711T3 (en) | 2012-08-31 | 2013-08-30 | Process for Preparation of Inter-species, Intra-Target Cross-Reactivity Antibody Molecules |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20150203840A1 (enExample) |
| EP (2) | EP2977386A1 (enExample) |
| JP (1) | JP6391574B2 (enExample) |
| CN (1) | CN104583238A (enExample) |
| AU (2) | AU2013310924B2 (enExample) |
| CA (1) | CA2878712A1 (enExample) |
| DK (1) | DK2890711T3 (enExample) |
| IL (1) | IL236523B (enExample) |
| IN (1) | IN2015DN00140A (enExample) |
| WO (1) | WO2014033252A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2686347T3 (pl) | 2011-03-16 | 2018-10-31 | Argenx Bvba | Przeciwciała przeciwko CD70 |
| MX377091B (es) | 2013-08-01 | 2025-03-07 | Ludwig Inst For Cancer Res Ltd | Proteina anti-garp y sus usos. |
| US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
| KR20190039937A (ko) | 2016-07-08 | 2019-04-16 | 스태튼 바이오테크놀로지 비.브이. | 항-ApoC3 항체 및 이의 사용 방법 |
| GB201612337D0 (en) | 2016-07-15 | 2016-08-31 | Argen-X N V | Ant-il-22r antibodies |
| CA3059133A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| GB201707561D0 (en) | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
| US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
| MA50516A (fr) | 2017-10-31 | 2020-09-09 | Staten Biotechnology B V | Anticorps anti-apoc3 et leurs procédés d'utilisation |
| MX2020006213A (es) | 2017-12-12 | 2020-09-14 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem2 y metodos relacionados. |
| GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
| CA3090321A1 (en) | 2018-02-05 | 2019-08-08 | Stichting Vu | Inverse agonistic anti-us28 antibodies |
| WO2020080941A1 (en) | 2018-10-16 | 2020-04-23 | Umc Utrecht Holding B.V. | Anti- low-density lipoprotein receptor-related protein 5/6 antibodies |
| WO2021241730A1 (ja) * | 2020-05-29 | 2021-12-02 | 第一三共株式会社 | 炎症性腸疾患に対する治療用抗体 |
| WO2022154664A1 (en) | 2021-01-15 | 2022-07-21 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer |
| WO2024096735A1 (en) | 2022-10-31 | 2024-05-10 | Stichting Amsterdam UMC | Single domain anti-cd169 antibodies |
| WO2024101989A1 (en) | 2022-11-08 | 2024-05-16 | Stichting Amsterdam UMC | Activation inducible antigen receptors for adoptive immunotherapy |
| EP4631501A1 (en) | 2024-04-09 | 2025-10-15 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Combinations of a calcium homeostasis disruptor with a death receptor 5 agonist for treating cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1034298E (pt) * | 1997-12-05 | 2012-02-03 | Scripps Research Inst | Humanização de anticorpo murino |
| CN1735629B (zh) * | 2002-11-08 | 2012-05-09 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子-α的单结构域抗体及其用途 |
| CA2505325C (en) * | 2002-11-08 | 2014-02-25 | Ablynx N.V. | Stabilized single domain antibodies |
| MXPA05010136A (es) * | 2003-03-24 | 2005-11-16 | Zymogenetics Inc | Anticuerpos anti-il-22ra, metodos y moleculas de enlace que se usan en la inflamacion. |
| CN1845937A (zh) * | 2003-03-24 | 2006-10-11 | 津莫吉尼蒂克斯公司 | 抗il－20抗体和结合伴侣以及在炎症中的使用方法 |
| EP2314623B1 (en) * | 2005-06-21 | 2012-07-04 | XOMA Technology Ltd. | IL-1beta binding antibodies and fragments thereof |
| TWI417301B (zh) * | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途 |
| US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
| GB2461546B (en) * | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| CN107337734A (zh) * | 2009-12-04 | 2017-11-10 | 弗·哈夫曼-拉罗切有限公司 | 多特异性抗体、抗体类似物、组合物和方法 |
| GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
| GB201002238D0 (en) * | 2010-02-10 | 2010-03-31 | Affitech As | Antibodies |
| PT2643019T (pt) * | 2010-11-24 | 2019-04-23 | Lexicon Pharmaceuticals Inc | Anticorpos para notum pectinacetilesterase |
-
2013
- 2013-08-30 DK DK13753659.5T patent/DK2890711T3/en active
- 2013-08-30 WO PCT/EP2013/067979 patent/WO2014033252A1/en not_active Ceased
- 2013-08-30 EP EP15181968.7A patent/EP2977386A1/en not_active Withdrawn
- 2013-08-30 CN CN201380044710.8A patent/CN104583238A/zh active Pending
- 2013-08-30 AU AU2013310924A patent/AU2013310924B2/en active Active
- 2013-08-30 JP JP2015529031A patent/JP6391574B2/ja active Active
- 2013-08-30 IN IN140DEN2015 patent/IN2015DN00140A/en unknown
- 2013-08-30 CA CA2878712A patent/CA2878712A1/en not_active Abandoned
- 2013-08-30 US US14/420,039 patent/US20150203840A1/en not_active Abandoned
- 2013-08-30 EP EP13753659.5A patent/EP2890711B1/en active Active
-
2014
- 2014-12-31 IL IL236523A patent/IL236523B/en active IP Right Grant
-
2017
- 2017-06-21 AU AU2017204188A patent/AU2017204188A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017204188A1 (en) | 2017-07-13 |
| EP2890711A1 (en) | 2015-07-08 |
| AU2013310924A1 (en) | 2015-01-29 |
| US20150203840A1 (en) | 2015-07-23 |
| IL236523B (en) | 2018-12-31 |
| CN104583238A (zh) | 2015-04-29 |
| EP2890711B1 (en) | 2017-01-04 |
| AU2013310924A8 (en) | 2015-04-30 |
| AU2013310924B2 (en) | 2017-08-03 |
| EP2977386A1 (en) | 2016-01-27 |
| CA2878712A1 (en) | 2014-03-06 |
| JP2015530087A (ja) | 2015-10-15 |
| IL236523A0 (en) | 2015-02-26 |
| WO2014033252A1 (en) | 2014-03-06 |
| JP6391574B2 (ja) | 2018-09-26 |
| IN2015DN00140A (enExample) | 2015-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2890711T3 (en) | Process for Preparation of Inter-species, Intra-Target Cross-Reactivity Antibody Molecules | |
| US11629434B2 (en) | Antibody screening methods | |
| US12442106B2 (en) | Sequence-based high throughput method generating camelids antibodies to cover broad epitopes with high-resolution | |
| AU2017221836B2 (en) | Comprehensive monoclonal antibody generation | |
| US9090994B2 (en) | Antibody humanization by framework assembly | |
| US20220073649A1 (en) | Mixed binding domains | |
| US20240287501A1 (en) | Means and Methods for Selection of Specific Binders | |
| EP2851427A1 (en) | Method for producing and obtaining variable domains of anti-digoxin monoclonal antibody fab fragment using the molecular biology cloning technique | |
| KR20240150779A (ko) | 고양이과 항체 라이브러리 | |
| HK40047350A (en) | Antibody screening methods | |
| HK40047350B (en) | Antibody screening methods |